

1/40




FIG. 1

2/40

LUV-SUV #2		Hepatic mRNA content (pg/ug)							
Rabbit #	Treatment	CETP	HMG-CoA R	LDL R	7a-hydroxylase	LDL ChE, day 1	LDL ChE, day 3	LDL ChE, day 5	LDL ChE, day 6
1	(A) PBS	2.87	0.54	4.27	0.56	7.4	7.1	5.2	6.5
2	(A) PBS	5.63	0.55	5.38	0.39	18.1	11.8	6.2	9.7
3	(A) PBS	5.34	0.39	8.93	0.74	8.5	8.9	4.4	8.7
4	(A) PBS	5.04	0.55	5.49	0.82	14.1	14.1	6.8	8.6
	Mean	4.72	0.51	6.02	0.83	11.53	10.48	6.15	8.38
	SEM	0.63	0.04	1.01	0.10	2.12	1.55	0.98	0.67
5	(B) LUV	3.15	0.58	7.23	0.63	25.3	14.9	13.6	10.5
6	(B) LUV	3.02	0.47	8.15	0.58	14.0	15.9	10.8	8.2
7	(B) LUV	2.52	0.58	4.81	0.83	28.3	22.5	21.3	22.4
8	(B) LUV	2.68	0.58	7.37	0.94	17.5	21.8	13.4	9.5
	Mean	2.84	0.55	8.69	0.75	21.28	16.78	14.78	12.85
	SEM	0.15	0.03	0.72	0.08	3.33	1.96	2.27	3.28
	1 vs. PBS	2.910	0.939	0.703	0.919	2.473	3.318	3.506	1.275
13	SUV + LUV	3.18	0.50	5.28	0.51	11.9	34.0	20.1	22.2
10	(C) SUV	5.64	0.38	3.98	0.30	21.1	45.3	15.3	46.3
11	(C) SUV	3.39	0.29	3.67	0.42	10.0	36.3	59.6	42.7
12	(C) SUV	3.00	0.13	3.34	0.63	17.8	31.8	45.5	22.3
	Mean w/o #13	4.01	0.27	3.66	0.45	16.30	37.80	40.13	37.10
	SEM w/o #13	0.02	0.07	0.18	0.10	3.28	3.97	13.07	7.47
	1 vs. PBS	0.686	2.903	2.295	1.304	1.220	6.414	2.594	3.628
	1 vs. LUV	1.397	3.660	4.328	2.301	1.963	4.296	1.912	2.98
	Mean w/ #13	3.80	0.33	4.07	0.47	15.20	38.86	35.13	33.38
	SEM w/ #13	0.62	0.06	0.42	0.07	2.57	2.96	10.51	8.48
	1 vs. PBS	1.041	2.091	1.781	1.369	1.103	7.890	2.748	3.848
	1 vs. LUV	1.512	2.763	3.369	2.554	1.445	8.085	1.893	2.856

FIG. 2

3/40

Plasma LDL cholesteryl ester concentrations
in response to injections of LUVs, SUVs, or saline





FIG. 3

4/40

Plasma LDL cholesteryl ester concentrations
in response to injections of LUVs, SUVs, or saline



"Mix" received SUVs on days 1, 3 & 5,
but also a dose of LUVs on day 3.
All other animals received single injections
on days 1, 3 & 5 (indicated by arrows).

FIG. 4

5/40

LDL receptor mRNA levels in liver in response
to injections of LUVs, SUVs, or saline




FIG. 5

6/40

LDL receptor mRNA levels in liver in response
to injections of LUVs, SUVs, or saline




FIG. 6

7/40

Cholesteryl ester transfer protein mRNA levels in liver
in response to injections of LUVs, SUVs, or saline




FIG. 7

8/40

7-alpha hydroxylase mRNA levels in liver in response
to injections of LUVs, SUVs, or saline




FIG. 8

*Indicates column of interest

9/40

Key points about LUV and atherosclerosis

1) Practical: Straight forward to manufacture
Non-toxic at very high doses

2) Mechanistic: Liposomes promote reverse
cholesterol transport *in vivo*

LUV are the optimal preparation

FIG. 9

10/40

Plasma unesterified cholesterol concentrations
in response to injections of LUV, SUV, or saline




FIG. 10

11/40

Plasma esterified cholesterol concentrations
in response to injections of LUV, SUV, or saline




FIG. 11

12/40

LDL esterified cholesterol concentrations
in response to injections of LUV, SUV, or saline




FIG. 12

13/40

VLDL esterified cholesterol concentrations
in response to injections of LUV, SUV, or saline




FIG. 13

14/40

HDL esterified cholesterol concentrations
in response to injections of LUV, SUV, or saline




FIG. 14

0094222-080704

15/40

HDL esterified cholesterol concentrations
in response to injections of LUV, SUV, or saline




FIG. 15

16/40




FIG. 16

17/40

Time course of LUV clearance in
control C57BL6 and ApoE KO mice




FIG. 17

18/40

- Effectiveness in humans

- Therapeutic targets

Lipid-rich, rupture-prone plaques
Critical Stenosis
Post-angioplasty re-stenosis
Atherosclerosis in general

FIG. 18

FIG. 18

19/40




FIG. 19

FIG. 19

20/40




FIG. 20

FIG. 20: 2000, 2010, 2020, 2030, 2040, 2050, 2060, 2070

21/40




FIG. 21

"Liposomal Compositions, and Methods of Using Liposomal
Compositions to Treat Dislipidemias"

22/40




FIG. 22

FIG. 22

23/40




FIG. 23




FIG. 24

25/40




FIG. 25

26/40

Plasma cholesterol ester concentrations




FIG. 26

27/40




FIG. 27

28/40




FIG. 28

29/40




FIG. 29




FIG. 30

30/40




FIG. 31




FIG. 32

31/40




FIG. 33




FIG. 34

32/40




FIG. 35




FIG. 36

33/40




FIG. 37




FIG. 38

34/40




FIG. 39




FIG. 40

35/40




FIG. 41




FIG. 42

36/40




FIG. 43




FIG. 44

37/40

CHOLESTEROL MOBILIZED BY THE LIPOSOMES TO THE RES




FIG. 45

CLEARANCE RATES OF VESICLES WITH REPEATED INFUSIONS




FIG. 46

38/40




FIG. 47




FIG. 48

39/40




FIG. 49




FIG. 50

40/40




FIG. 51